// App-Quantinova.ai

TPS3101 : Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Researchers

Presenter

  • Crystal Mackall

Principal Investigators

  • Sandra P. D'Angelo

  • Stephan A. Grupp

  • Kunle Odunsi

  • Mihaela C. Cristea

  • Gerald P. Linette

  • Harriet M. Kluger

  • Gabor Kari

  • Lini Pandite

  • Tom Holdich

  • Elliot Norry

  • Gwendolyn Binder-Scholl

  • Rafael G. Amado

Medical Centers

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Roswell Park Cancer Institute, Buffalo, NY

  • Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA

  • Washington University, St Louis, MO

  • Yale University School of Medicine, New Haven, CT

  • Adaptimmune, Philadelphia, PA

  • Adaptimmune, Abingdon, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • New York esophageal squamous cell carcinoma 1

  • Major Histocompatibility Complex, Class I, A

Drug/Treatment

  • NY-ESO-1c259

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • NCT01352286

  • NCT01892293

  • NCT01343043

  • NCT01567891

  • NCT01350401

  • NCT02588612

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved